In line with these findings, a higher ratio of CD163+ of CD68+ (CD163/CD68) TAMs and higher serum levels of CD163 correlate with higher tumor grade, worse PFS and early relapse of serous ovarian carcinoma after first-line therapy [45,46,47,48,49]. This evidence concerns the gene CD163 and ovarian serous carcinoma.